.jpg)
- May 5
Aravax appoints Dr Brett Haumann to Board of Directors
06 May 2022, Melbourne, AUSTRALIA: Aravax, a clinical stage biotechnology company focused on developing the most advanced novel therapy...
- Mar 3
Aravax opens IND for PVX108 Phase 2 trials and strengthens SAB
Phase 2 study of PVX108 to commence in United States and Australia Dr Robert A. Wood, professor of pediatrics at the Johns Hopkins...
- Aug 26, 2021
Aravax appoints Principal Investigators for PVX108 Phase 2 trials in United States and Australia
27 August 2021, Melbourne, AUSTRALIA: Aravax, a clinical stage biotechnology company focused on developing the first therapy for peanut...
- Jul 12, 2021
Aravax presents PVX108 Phase 1 longitudinal immunology data at EAACI 2021.
13 July 2021, Melbourne, AUSTRALIA: Aravax, a clinical stage biotechnology company focused on developing the first therapy for peanut...
- Oct 31, 2020
Aravax appoints Financial Executive Thomas Ulmer to Board of Directors
01 November, 2020, Melbourne, Victoria - Aravax, a clinical stage biotechnology company focused on developing the first safe and rapidly...
- Sep 29, 2019
Aravax receives positive pre-IND feedback from FDA on PVX108 Phase 2 trial plans.
30 September 2019, Melbourne, AUSTRALIA: Aravax, a clinical stage biotechnology company focused on developing the first therapy for...